menu
    • menu
    [{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center"},{"orgOrder":0,"company":"Ministry of Health, Sri Lanka","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SRI LANKA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Ministry of Health, Sri Lanka","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ministry of Health, Sri Lanka \/ World Health Organization","highestDevelopmentStatusID":"7","companyTruncated":"Ministry of Health, Sri Lanka \/ World Health Organization"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Servier | LivaNova","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ Servier | LivaNova","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Clermont-Ferrand \/ Servier | LivaNova"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ European Commission","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ European Commission"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Nanfang Hospital, Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Nanfang Hospital, Southern Medical University","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Nanfang Hospital, Southern Medical University"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arbor Pharmaceuticals \/ Azurity Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Enalapril Maleate

    Menu

    Enalapril Maleate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arbor Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Arbor Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Azurity Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

                            Details : The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.

                            Product Name : Epaned

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 24, 2021

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Azurity Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Second Affiliated Hospital, Zhejiang University

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Second Affiliated Hospital, Zhejiang University

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertens...

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2021

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of ...

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2016

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 12, 2016

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 12, 2016

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ethicare

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability Study With Enalapril in Healthy Volunteers

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2014

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of HYpertension: Morning Versus Evening

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2014

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shenzhen Ausa Pharmed Co.,Ltd

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Shenzhen Ausa Pharmed Co.,Ltd

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Nanfang Hospital, Southern Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CSPPT- Chronic Kidney Diseases Study

                            Details : Enalapril Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 07, 2013

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Nanfang Hospital, Southern Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ministry of Health, Sri Lanka

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ministry of Health, Sri Lanka

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain...

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2012

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Servier | LivaNova

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?

                            Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2011

                            Lead Product(s) : Enalapril Maleate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Servier | LivaNova

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth